Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00977574 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

349

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Recurrent Malignant Uterine Corpus Neoplasm
Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Carboplatin
DRUG: Ixabepilone
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)

Collaborators

NRG Oncology